Research location
Toshima City
Tokyo, Japan
Advertisement
Research activity in Toshima City
Tokyo, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Toshima City
9 linked trials · page 1 of 1A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusNCT05086445 · 2021-11-12 · 1 site observation
COMPLETED
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled AsthmaNCT04946318 · 2021-09-08 · 1 site observation
TERMINATED
Special Drug Use Surveillance for Entresto TabletsNCT04781881 · 2021-03-04 · 1 site observation
COMPLETED
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled AsthmaNCT04410523 · 2020-09-09 · 1 site observation
TERMINATED
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisNCT01850966 · 2012-09-12 · 1 site observation
COMPLETED
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseNCT01251718 · 2010-12-01 · 1 site observation
COMPLETED
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-NCT01129596 · 2010-06-10 · 1 site observation
COMPLETED
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mgNCT00919477 · 2009-05-01 · 1 site observation
COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive DisorderNCT00798707 · 2008-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.